Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of cannabidiol for steroid-sparing treatment in steroid-dependent Crohn's disease
MOH_2019-05-12_007126Phase 2Not yet recruiting
- Sponsor
- STERO Biotechs
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing CBD with Placebo (2 arms). Primary endpoints: Safety and tolerability of cannabidiol and Steroid-sparing efficacy. Planned start May 2019; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2019-05-12_007126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-12_007126.